# Fairmount Funds Management > Fairmount Funds Management is a VC fund backing Biotechnology and Health Care. See 37 investments, check sizes, portfolio and contact details. Updated Aug 2026. - Type: VC Fund - Location: Philadelphia, United States - Total investments: 37 - Last investment: Jul 2026 - Lead investor: 35% - Last updated: Aug 2026 - Website: https://www.fairmountfunds.com/ Fairmount Funds Management is a Philadelphia-based investment firm. ## Contacts 5 contacts available for Fairmount Funds Management. Shizune tracks 1 team members at Fairmount Funds Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/fairmount-funds-management?utm_source=investor_profile ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 16 | 43% | | Health Care | 14 | 38% | | Therapeutics | 11 | 30% | | Biopharma | 7 | 19% | | Pharmaceutical | 6 | 16% | 10 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Post-IPO Equity | 14 | 38% | | Series A | 4 | 11% | | Series B | 3 | 8% | | Funding Round | 2 | 5% | | Seed | 1 | 3% | 6 stages tracked in total. ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 15 | 41% | | France | 1 | 3% | | Denmark | 1 | 3% | | United Kingdom | 1 | 3% | ## Team | Name | Title | Investments | Profile | | --- | --- | --- | --- | | Peter Harwin | Co-Founder and Managing Member | 3 | https://shizune.co/investors/profile/peter-harwin | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Mentari Therapeutics | Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M | Private Equity | Jul 22, 2026 | | | Crescent Biopharma | Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors. | $185M | Post-IPO Equity | Dec 04, 2025 | | | Galecto | Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $284.9M | Post-IPO Equity | Nov 10, 2025 | | | Galecto | Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $284.9M | Post-IPO Equity | Nov 10, 2025 | | | Galecto | Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $284.9M | Post-IPO Equity | Nov 10, 2025 | | | Jade Biosciences | Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. | $135M | Post-IPO Equity | Oct 07, 2025 | | | Oruka Therapeutics | Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases. | $180M | Post-IPO Equity | Sep 17, 2025 | | | Crescent Biopharma | Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors. | $200M | Post-IPO Equity | Jun 16, 2025 | | | Jade Biosciences | Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. | $300M | Post-IPO Equity | Apr 29, 2025 | | | Interius BioTherapeutics | Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M | | Jan 01, 2025 | | 10 of 37 investments shown. ## Co-investors - [Venrock Healthcare Capital Partners](https://shizune.co/investors/profile/venrock-healthcare-partners) — VC Fund, 26 deals together - [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 17 deals together - [Commodore Capital](https://shizune.co/investors/profile/commodore-capital) — VC Fund, 12 deals together - [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 11 deals together - [Wellington Management](https://shizune.co/investors/profile/wellington-management) — VC Fund, 11 deals together - [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 10 deals together ## Similar investors ### Similar stage - [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund - [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund - [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund ## FAQ ### What does Fairmount Funds Management invest in? Fairmount Funds Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series A stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### How do I contact Fairmount Funds Management? Public channels for Fairmount Funds Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox. ### Who are the partners at Fairmount Funds Management? The team at Fairmount Funds Management includes Peter Harwin (Co-Founder and Managing Member). The Team section lists each member with their title, investment count and links. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co